Form 4 for VNDA Vanda Pharmaceuticals Inc.
Accepted 2025-02-24 00:00:00 ET · period of report 2025-02-21 · accession 0000950170-25-025914 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-02-24 | 2025-02-21 | VNDA | Moran Kevin Patrick | SVP, CFO, Treas | P - Purchase | $4.39 | +2,000 | 355.8K | +0.6% | +$8,780 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-21 | P | A | 2,000 | $4.39 | 355,763 | D | — | — |